Life Science Angels

Founded in 2018, Trio Pharmaceuticals is a biopharmaceutical company based in San Diego, California. It specializes in developing innovative cancer therapeutics that directly inhibit tumor growth and selectively target immunosuppression within tumors, without relying on current immune checkpoint pathways.

Pelvital USA, Inc. is a privately held company based in Minneapolis, Minnesota, focused on restoring pelvic health and enhancing the quality of life for individuals suffering from pelvic floor disorders. Founded in 2016, the company is currently evaluating the Flyte system, an investigational medical device designed to strengthen and potentially heal the pelvic floor muscle system. This device employs a unique mechanotherapy technology, which has been shown to effectively heal and strengthen muscle systems. Through its innovative approach, Pelvital aims to provide significant improvements for patients dealing with pelvic floor issues.

Neurava specializes in developing wearable diagnostic devices for epilepsy patients. Their products monitor health metrics, alert users and healthcare providers to seizures and cardiorespiratory dysfunctions, enabling timely intervention and improved treatment outcomes.

Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

Avisi Technologies Inc. is a Philadelphia-based company founded in 2017 that specializes in developing innovative solutions for glaucoma treatment. Its primary product, VisiPlate, is a next-generation, nanotechnology-enabled aqueous shunt designed to prevent blindness caused by glaucoma. Through its advanced technology, Avisi Technologies aims to enhance the effectiveness of glaucoma management and improve patient outcomes.

InnoSIGN develops an mRNA-based pathway activity profiling technology to advance precision medicine by providing deeper insight into disease mechanisms. It builds a substantial library of pathway activity profiles to support diagnostics and drug development, and offers researchers access to qPCR tests for decentralized use via a service testing facility in the Netherlands.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

Strategikon Pharma, Inc. is a technology company based in San Rafael, California, founded in 2016. It specializes in developing software solutions that streamline the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a comprehensive software platform designed for the end-to-end management of clinical business operations, including planning, outsourcing, and budgeting for clinical trials. This innovative software replaces traditional, labor-intensive methods, often reliant on Excel, which are costly and inefficient. Clinical Maestro integrates workflows to enhance communication and data sharing between biopharmaceutical companies and their outsourcing partners. The platform facilitates clinical financial management, vendor performance metrics, and contract lifecycle management, while also offering consulting services for new clinical business operations. Case studies with leading pharmaceutical companies have shown that Clinical Maestro can lead to significant savings and improved accuracy in budgeting, demonstrating its effectiveness in transforming clinical trial management.

Visicell Medical develops innovative stem cell tracking tools designed to enhance the safety and efficacy of regenerative therapies. Their biodegradable tools enable real-time tracking of injected stem cells in both clinical and pre-clinical settings, aiming to improve treatment outcomes for patients with incurable diseases.

Avisi Technologies Inc. is a Philadelphia-based company founded in 2017 that specializes in developing innovative solutions for glaucoma treatment. Its primary product, VisiPlate, is a next-generation, nanotechnology-enabled aqueous shunt designed to prevent blindness caused by glaucoma. Through its advanced technology, Avisi Technologies aims to enhance the effectiveness of glaucoma management and improve patient outcomes.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

Saccharo is a biotech start-up focused on immuno-oncology, dedicated to developing innovative therapeutic products for cancer treatment and other diseases. Founded in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California, the company has identified a unique polysaccharide that envelops human cancer cells. This polysaccharide enables a novel mechanism of action for its therapies, which are designed to provide multiple killing effects while maintaining a favorable safety profile and broad therapeutic window. Saccharo's approach aims to enhance treatment options across various cancer types, potentially improving outcomes for patients.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Strategikon Pharma, Inc. is a technology company based in San Rafael, California, founded in 2016. It specializes in developing software solutions that streamline the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a comprehensive software platform designed for the end-to-end management of clinical business operations, including planning, outsourcing, and budgeting for clinical trials. This innovative software replaces traditional, labor-intensive methods, often reliant on Excel, which are costly and inefficient. Clinical Maestro integrates workflows to enhance communication and data sharing between biopharmaceutical companies and their outsourcing partners. The platform facilitates clinical financial management, vendor performance metrics, and contract lifecycle management, while also offering consulting services for new clinical business operations. Case studies with leading pharmaceutical companies have shown that Clinical Maestro can lead to significant savings and improved accuracy in budgeting, demonstrating its effectiveness in transforming clinical trial management.

Anubis Bio is a pet health company that develops natural food products to manage digestive issues in animals. Its flagship product, DoggyStat, rapidly resolves diarrhea in dogs and cats by delivering immune factors to the gastrointestinal tract.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

iDentical specializes in personalized dental implant solutions. Founded in 2018, the company uses advanced 3D technology to create drill-free, patient-specific dental implants, making tooth replacement more accessible and affordable worldwide.

Founded in 2013, BioTrace Medical specializes in manufacturing a cardiac pacing device designed to treat reversible symptomatic bradycardia. The company aims to improve patient outcomes and reduce hospital costs by reinventing temporary pacing.

Stimwave Technologies, Inc., established in 2010, is a medical device company based in Scottsdale, Arizona. It specializes in the development, manufacturing, and marketing of wireless, microsize injectable medical devices for neurology markets. The company's flagship product, the Freedom SCS System, is a spinal cord stimulator used to alleviate chronic low back and leg pain. Additionally, Stimwave offers the StimQ PNS System, a peripheral nerve stimulator that targets specific nerves to treat chronic pain. Both products utilize the company's proprietary MicroStim wireless technology. Stimwave operates under the name Stimwave Technologies, Inc., following a rebrand from its former name, Neural Micro Incorporated.

Eumentis Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics for neurodevelopmental and neurodegenerative diseases. Based in Newton, Massachusetts, the company is working on several product candidates, including EM-036, a nitroaminoadamantane NMDA receptor antagonist targeted at treating Alzheimer's disease and autism-spectrum disorders. Additionally, Eumentis is developing EM-221, an oral PDE10A inhibitor aimed at modulating the dopamine D2 pathway in the striatum, specifically for neuropsychiatric conditions. Founded in 2019, Eumentis combines established therapeutic knowledge with cutting-edge insights into brain function to enhance treatment options within the healthcare industry.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, that specializes in developing medical products and research tools focused on male fertility management. Founded in 2012, the company manufactures innovative devices such as the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a tool for remote blood sampling that facilitates comprehensive diagnostic testing. Additionally, Sandstone offers the Trak fertility system, which includes an engine, a disposable test plate, a sample collection cup, and a dropper, enabling men to monitor their sperm quality and take proactive steps toward improving their fertility. The accompanying Trak mobile application allows users to track their fertility data over time, identify potential fertility issues, and enhance their chances of conception. Sandstone Diagnostics aims to empower couples to manage their reproductive health in the comfort and privacy of their homes.

Founded in 2016, S2 Genomics develops integrated sample preparation systems that process tissues and liquid samples into genomic samples. Its core technology is spatial sequencing, which captures three-dimensional coordinates of single cells within tissue for next-generation sequencing readout.

Inhalon Biopharma, Inc. is a biotechnology company focused on developing monoclonal antibodies aimed at treating and preventing respiratory infections. Founded in 2018 and based in Carrboro, North Carolina, Inhalon utilizes a unique technology that allows for the trapping of pathogens in mucus secretions. This innovative approach is particularly effective in addressing respiratory syncytial virus (RSV), a significant cause of lung and respiratory tract infections in children. The company's inhaled immunotherapy platform leverages biologics for mucosal applications, enhancing the ability to trace and combat pathogens associated with various acute respiratory infections.

Founded in 2016, S2 Genomics develops integrated sample preparation systems that process tissues and liquid samples into genomic samples. Its core technology is spatial sequencing, which captures three-dimensional coordinates of single cells within tissue for next-generation sequencing readout.

VALFIX Medical is a Tel Aviv-based medical device company focused on transcatheter solutions for repairing and replacing the mitral and tricuspid valves, using multi-wire technology to provide a complete transcatheter repair and replacement approach, offering an alternative to open-heart surgery and addressing heart failure symptoms by eliminating mitral regurgitation.

Embolx develops and manufactures catheter-based devices for localized cancer therapy. Its flagship product, Sniper, is a drug delivery balloon microcatheter that offers precise tracking, controlled delivery, efficient tumor fill, and reduced non-target flow.

Chimera Bioengineering develops engineered cell therapies to enhance the body's ability to fight cancer. The company focuses on chimeric antigen receptor (CAR) T-cell approaches and aims to redesign the immune response to overcome cancer’s ability to evade detection. Its technology uses drug-responsive gene regulators to reprogram the software of the immune system, with the goal of minimizing toxicity, increasing efficacy, and extending CAR-T cell persistence. This approach seeks to improve safety and effectiveness for patients with cancers that are difficult to treat, including liquid tumors and certain solid tumors. Chimera Bioengineering develops therapies intended to boost T-cell recognition and tumor targeting, enabling longer-lasting, personalized treatments for advanced cancers. Through research and development, the company aims to broaden the impact of cell therapies beyond current options and move toward cures for patients unresponsive to standard therapies.

Chameleon Biosciences Inc. is a biotechnology company focused on developing Adeno Associated Virus (AAV) based gene therapies aimed at treating rare genetic diseases. Founded in 2017 and headquartered in San Anselmo, California, the company utilizes innovative gene delivery technology to effectively administer therapeutic proteins to targeted tissues while minimizing immune responses to both the delivery vector and the therapeutic agents. This approach enhances gene delivery efficiency, reduces the immunogenicity of treatments, and expands the potential applications for patients with genetic disorders. Chameleon Biosciences is dedicated to addressing the significant challenges posed by genetic diseases, particularly in children, and strives to provide effective treatment options that allow for multiple systemic dose administrations, ensuring that affected individuals receive personalized care as their conditions evolve.

TeVido BioDevices, Inc. is a biotech start-up based in Austin, Texas, focused on developing innovative tissue-engineered products for reconstructive surgery. Established in 2016, the company utilizes a platform technology that integrates 3D bio-printing with patients' living cells to create custom grafts. These grafts specifically address unmet needs in reconstructive and cosmetic surgery, particularly for individuals who have lost skin color due to scarring or disease. TeVido's approach aims to enhance the quality of life and self-esteem of those affected by disfigurement while also having potential applications in wound healing and broader cosmetic procedures. Through its advanced manufacturing techniques and cellular therapy innovations, TeVido BioDevices is poised to significantly improve surgical outcomes in the field of reconstructive medicine.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Founded in 2016, S2 Genomics develops integrated sample preparation systems that process tissues and liquid samples into genomic samples. Its core technology is spatial sequencing, which captures three-dimensional coordinates of single cells within tissue for next-generation sequencing readout.

TransformativeMed, Inc. is a healthcare technology company based in Seattle, Washington, founded in 2007. The company specializes in developing software solutions that enhance hospital operations and improve patient care. Its primary offerings include Smart Health Apps, which integrate with electronic medical record (EMR) data and clinician workflows. Key products are CORES Smart Handoffs, allowing seamless patient sign-outs between providers; GlycemiCare Smart Glucose, which supports inpatient teams in managing glycemic control to enhance patient safety; and ACR Select Smart Imaging, providing imaging decision support directly within the EMR at the point of order entry. TransformativeMed's platform translates critical patient data into actionable insights, enabling healthcare professionals to focus more on patient outcomes and streamline their processes.

Founded in 2017, Purissima is a biotherapeutics company based in Sunnyvale, California. It specializes in producing active pharmaceutical ingredient (API) grade molecules through the fermentation of heterotrophic microalgae.

Virion Therapeutics, established in 2018 and based in Newark, Delaware, is a biotechnology company focused on developing immune-based treatments for virally-associated cancers and chronic viral infections. The company's primary products are ChiVax and ChiVax-gD vaccines, designed to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have demonstrated promising results in pre-clinical testing and are poised for translation into clinical trials targeting diseases such as HPV-induced cancers and chronic Hepatitis B infections.

Ark.one Health develops a predictive analytics platform designed to identify cost-saving opportunities and optimize financial performance for healthcare systems. The company's proprietary algorithm-based analysis enables clients to enhance decision-making and improve operational efficiency.

Seal Rock Therapeutics develops small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company focuses on treating hepatic indications like NASH, with additional opportunities in cardiac, immunological, and neurodegenerative areas.

TheraDep specializes in the development of advanced surface coatings for microneedles and labware, focusing on applications in the medical device and pharmaceutical sectors. The company offers biocompatible, drug-eluting, growth-promoting, and therapeutic coatings, utilizing a novel patented process. By collaborating with medical device and labware manufacturers, TheraDep provides customized solutions that address specific needs in drug delivery and patient treatment, enhancing the effectiveness and safety of medical applications.

InvVax develops innovative vaccines using its proprietary platform. Its flagship product is a universal influenza vaccine designed to provide broad, long-lasting protection against all flu strains.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

Nanotech Biomachines specializes in advanced sensor technology aimed at transforming therapeutic discovery and development. The company leverages modern electronic materials and straightforward membrane preparations to achieve high sensitivity and specificity in measuring real-time binding to integral membrane proteins (IMPs). This innovative approach is mass-independent, cell-free, and label-free, allowing for direct electronic output using native IMPs in fluid membranes. By providing clients with this cutting-edge sensor technology, Nanotech Biomachines enhances the efficiency and effectiveness of the drug discovery process, positioning itself at the forefront of 21st-century medicine development.

Seal Rock Therapeutics develops small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company focuses on treating hepatic indications like NASH, with additional opportunities in cardiac, immunological, and neurodegenerative areas.

Embolx develops and manufactures catheter-based devices for localized cancer therapy. Its flagship product, Sniper, is a drug delivery balloon microcatheter that offers precise tracking, controlled delivery, efficient tumor fill, and reduced non-target flow.

InvVax develops innovative vaccines using its proprietary platform. Its flagship product is a universal influenza vaccine designed to provide broad, long-lasting protection against all flu strains.

Embolx develops and manufactures catheter-based devices for localized cancer therapy. Its flagship product, Sniper, is a drug delivery balloon microcatheter that offers precise tracking, controlled delivery, efficient tumor fill, and reduced non-target flow.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Thrive Bioscience specializes in life science technologies. It offers automated non-microbial cell culture instruments for research, drug discovery, and regenerative medicine markets. Its flagship product, CellAssist, enables researchers to image, analyze, and document cells and workflow details centrally.

InvVax develops innovative vaccines using its proprietary platform. Its flagship product is a universal influenza vaccine designed to provide broad, long-lasting protection against all flu strains.

Retrotope Inc. is a biotechnology company based in Los Altos, California, focused on developing innovative therapeutics for degenerative diseases. Founded in 2006, Retrotope specializes in preserving and restoring mitochondrial health, addressing conditions associated with oxidative stress. The company’s primary therapeutic candidates target a range of neurological disorders, including Parkinson's disease, Alzheimer's disease, and specific mitochondrial myopathies. Notably, Retrotope is developing RT001, a drug aimed at treating infantile neuroaxonal dystrophy. Through its unique drug platform, Retrotope employs isotope effects to mitigate cellular damage caused by lipid peroxidation, positioning itself as a leader in the treatment of intractable and degenerative disorders. The company engages in multiple discovery and development programs, emphasizing its commitment to advancing healthcare solutions for challenging neurological conditions.

Ask.Vet is an online platform that connects pet owners with licensed veterinarians, offering expert advice on a variety of topics related to animal care and well-being. Designed to serve the needs of the two hundred million households with pets worldwide, Ask.Vet allows users to pose questions that are directed to trained veterinarians who provide guidance, education, and referrals to local veterinary services for further diagnosis and treatment. The platform emphasizes a personalized experience, addressing issues ranging from general wellness and nutrition to specific health concerns. Additionally, veterinarians, clinics, and service providers can pay a referral fee to Ask.Vet for qualified leads, enhancing the platform's ecosystem for both pet owners and veterinary professionals.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in developing and commercializing innovative tools for protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. By utilizing microfluidics technology, the scWestern system partitions single cells into micro-wells, lyses them, and performs SDS-PAGE separation on each cell lysate. This technology facilitates the identification of cellular subpopulations, the analysis of enriched cell populations post-FACS sorting, and studies on cell signaling and cancer heterogeneity, among other applications. Researchers leverage Zephyrus's products to gain deeper insights into various biological fields, including cancer, stem cells, neurology, and human disease development, ultimately aiming to enhance healthcare outcomes.

Nanotech Biomachines specializes in advanced sensor technology aimed at transforming therapeutic discovery and development. The company leverages modern electronic materials and straightforward membrane preparations to achieve high sensitivity and specificity in measuring real-time binding to integral membrane proteins (IMPs). This innovative approach is mass-independent, cell-free, and label-free, allowing for direct electronic output using native IMPs in fluid membranes. By providing clients with this cutting-edge sensor technology, Nanotech Biomachines enhances the efficiency and effectiveness of the drug discovery process, positioning itself at the forefront of 21st-century medicine development.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Gemmus Pharma Inc., established in 2007 and headquartered in San Francisco, California, is a biotechnology company focused on developing therapeutics for the treatment of influenza and other infectious diseases. The company's primary product candidates are GP1001 and GP1681. GP1001, a non-peptidic eiconsanoid analog, is intended for treating severe influenza infections requiring hospitalization, serving as either a standalone therapy or in combination with antiviral drugs like oseltamivir. Meanwhile, GP1681 aims to alleviate influenza symptoms by moderating the viral-induced cytokine response. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Diseases (NIAID) and plans to submit an Investigational New Drug (IND) application to the FDA for its influenza treatment in 2014.

Physcient, Inc. is a medical device company based in Durham, North Carolina, established in 2007. The company specializes in the manufacturing of the Differential Dissector, a surgical instrument designed for blunt dissection. This device is utilized in a variety of surgical fields, including plastic surgery and open general surgical procedures such as thoracic, gastrointestinal, gynecological, urological, peripheral vascular, and orthopedic surgeries. Physcient focuses on developing modern technology for handheld surgical instruments that aim to facilitate faster patient recovery while maintaining existing surgical procedures. The founding team comprises three scientists and executives with extensive experience in innovating technologies for the life and health sciences.

Carmenta Bioscience, Inc. is a privately held medical technology company focused on enhancing maternal and fetal health through innovative diagnostics. Established in 2012 and based in Palo Alto, California, the company specializes in developing a highly accurate serum-based diagnostic test for preeclampsia. Carmenta Bioscience emerged from the Stanford University School of Medicine and employs a systems biology approach to improve the diagnosis and prediction of this serious condition. As of 2015, it operates as a subsidiary of Progenity, Inc.

NuMedii, Inc. is a biotechnology company focused on the discovery, development, and out-licensing of innovative drug candidates. Founded in 2008 and based in San Mateo, California, the company leverages its proprietary Life Sciences Big Data technology, initially developed in Atul Butte’s lab at Stanford University, to analyze an extensive range of biological, pharmacological, and clinical data. This approach enables NuMedii to uncover new therapeutic opportunities and de-risk existing drugs by identifying novel indications and potential patient subgroups. By forming strategic partnerships with pharmaceutical companies, NuMedii aims to advance the clinical development and commercialization of its de-risked drug candidates, thereby addressing unmet medical needs across various diseases.

NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.

nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Gemmus Pharma Inc., established in 2007 and headquartered in San Francisco, California, is a biotechnology company focused on developing therapeutics for the treatment of influenza and other infectious diseases. The company's primary product candidates are GP1001 and GP1681. GP1001, a non-peptidic eiconsanoid analog, is intended for treating severe influenza infections requiring hospitalization, serving as either a standalone therapy or in combination with antiviral drugs like oseltamivir. Meanwhile, GP1681 aims to alleviate influenza symptoms by moderating the viral-induced cytokine response. Gemmus Pharma has received support from the National Institute of Allergy and Infectious Diseases (NIAID) and plans to submit an Investigational New Drug (IND) application to the FDA for its influenza treatment in 2014.

Niveus Medical, Inc. is a healthcare company that specializes in developing muscle stimulation systems aimed at preventing muscle atrophy, particularly in the quadriceps. Founded in 2008 and located in Palo Alto, California, Niveus Medical focuses on providing effective stimulation to key muscle groups during periods of sedation and bed rest, such as in intensive care unit (ICU) settings. The company's technology enhances local blood circulation and is indicated for maintaining or increasing the range of motion of the knee joint. Its systems are designed to facilitate muscle re-education, prevent disuse atrophy, and alleviate muscle spasms, ultimately promoting faster recovery for patients and increasing the likelihood of successful treatment outcomes. The company operates under the brand IntelliSTIM.

MoMelan Technologies, Inc. is a company based in Cambridge, Massachusetts, that specializes in developing innovative devices for the treatment of skin disorders. Established in 2009, the company focuses on a tabletop device designed to enhance the surface area of skin grafts. By taking a small sample of harvested skin and expanding it by approximately 100 times, the device enables effective grafting onto damaged areas, such as scars. MoMelan Technologies operates as a subsidiary of Acelity L.P. Inc., further emphasizing its commitment to advancing medical solutions in dermatology.

OncoHealth is a company that specializes in the development of screening devices aimed at detecting and diagnosing cancer. Its innovative technology focuses on the creation of protein bio-markers specifically for the screening and diagnostics of cervical cancer and other cancers associated with the human papillomavirus (HPV). By providing advanced tools for medical professionals, OncoHealth enhances the ability to monitor, diagnose, and treat cancer, ultimately contributing to improved patient outcomes in oncology.

OncoHealth is a company that specializes in the development of screening devices aimed at detecting and diagnosing cancer. Its innovative technology focuses on the creation of protein bio-markers specifically for the screening and diagnostics of cervical cancer and other cancers associated with the human papillomavirus (HPV). By providing advanced tools for medical professionals, OncoHealth enhances the ability to monitor, diagnose, and treat cancer, ultimately contributing to improved patient outcomes in oncology.

Allylix, Inc. is an early-stage biotechnology company specializing in the development of terpene products and their derivatives. Founded in 2002 and headquartered in San Diego, California, with research and development laboratories in Lexington, Kentucky, the company focuses on applications across various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Among its notable products is nootkatone, a grapefruit flavor utilized in fruit juices and citrus-flavored sodas. Allylix also develops sesquiterpenes for the aroma chemical segment of the flavor and fragrance market, as well as production platforms aimed at pharmaceutical, nutraceutical, and agricultural applications.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Vaxart is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, influenza, RSV, and HPV, with products administered via convenient room-temperature stable tablets.

Velomedix, Inc. is a therapeutic hypothermia company based in Menlo Park, California. The company specializes in technologies designed to protect the body’s organs during ischemic or inflammatory insults. Velomedix's innovative approach aims to provide an effective solution for preserving organ function in critical medical situations.

Verdezyne is a private company specializing in synthetic biology, focusing on the production of chemicals from renewable sources. The company leverages its expertise in biological science and proprietary computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. Through this innovative approach, Verdezyne aims to optimize commercial fermentation processes, allowing for the creation of sustainable alternatives to petrochemicals. Its platform combines advanced biological techniques with proven manufacturing technologies, enabling the production of a wide range of chemical building blocks and additives used in everyday products. By reducing dependence on oil, Verdezyne provides cost-effective and environmentally friendly solutions in the chemical industry.

Founded in 2005, Breathe Technologies develops innovative respiratory therapies aimed at improving patients' mobility and quality of life. The company specializes in lightweight, portable ventilator systems designed for use in hospitals and homes, targeting conditions such as interstitial lung diseases, neuromuscular disorders, and post-transplant care.

Satoris specializes in the development of neurodiagnostic tests aimed at identifying neurological diseases, including Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses. By focusing on the convenience and affordability of these tests, Satoris aims to enhance patient care while simultaneously reducing healthcare costs.

Allylix, Inc. is an early-stage biotechnology company specializing in the development of terpene products and their derivatives. Founded in 2002 and headquartered in San Diego, California, with research and development laboratories in Lexington, Kentucky, the company focuses on applications across various markets, including flavor and fragrance, food ingredients, pharmaceuticals, agriculture, and biofuels. Among its notable products is nootkatone, a grapefruit flavor utilized in fruit juices and citrus-flavored sodas. Allylix also develops sesquiterpenes for the aroma chemical segment of the flavor and fragrance market, as well as production platforms aimed at pharmaceutical, nutraceutical, and agricultural applications.

Vaxart is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, influenza, RSV, and HPV, with products administered via convenient room-temperature stable tablets.

Fluxion Biosciences, founded in 2005, specializes in developing analytical instruments and kits for functional cellular analyses in life science, drug discovery, and diagnostic applications. Its flagship products include the IsoFlux Liquid Biopsy System for enriching rare cell populations like circulating tumor cells, and BioFlux systems for live cell analysis under shear flow, used across various research fields. Additionally, Fluxion offers IonFlux systems for automated patch clamping and provides analytical services for liquid biopsy applications. Serving biotechnology and pharmaceutical companies, academic institutions, and government research organizations, Fluxion distributes its solutions through a network of international distributors, with headquarters in Alameda, California.

Verdezyne is a private company specializing in synthetic biology, focusing on the production of chemicals from renewable sources. The company leverages its expertise in biological science and proprietary computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. Through this innovative approach, Verdezyne aims to optimize commercial fermentation processes, allowing for the creation of sustainable alternatives to petrochemicals. Its platform combines advanced biological techniques with proven manufacturing technologies, enabling the production of a wide range of chemical building blocks and additives used in everyday products. By reducing dependence on oil, Verdezyne provides cost-effective and environmentally friendly solutions in the chemical industry.

VasoNova, Inc. is a medical device manufacturer based in Sunnyvale, California, specializing in vascular navigation systems for healthcare providers and clinicians. The company is known for its innovative self-guided PICC catheter and the VasoNova Vascular Positioning System, which employs an algorithm-based approach to facilitate the optimal placement of vascular access devices. Through its advanced technologies, VasoNova aims to enhance the efficiency and accuracy of vascular access procedures in clinical settings.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Verdezyne is a private company specializing in synthetic biology, focusing on the production of chemicals from renewable sources. The company leverages its expertise in biological science and proprietary computational algorithms to design and synthesize diverse gene libraries for engineering proteins, metabolic pathways, and microorganisms. Through this innovative approach, Verdezyne aims to optimize commercial fermentation processes, allowing for the creation of sustainable alternatives to petrochemicals. Its platform combines advanced biological techniques with proven manufacturing technologies, enabling the production of a wide range of chemical building blocks and additives used in everyday products. By reducing dependence on oil, Verdezyne provides cost-effective and environmentally friendly solutions in the chemical industry.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.